- Poster Session
Posters 7: Oncology - Bladder
Sunday June 26, 2022
|
07:30 to 09:00
Room: Ash
Learning Objectives
As a result of attending this session, participants will be able to:
- Describe the following regarding Bacillus Calmette-Guérin treatment:
-
- Understand sex-based differences in response
- How basophils count may predict recurrence and progression
- Impact of routine bladder biopsies after Bacillus Calmette-Guerin treatment in patients with pure carcinoma in situ of the bladder
- Tumor adjacent tertiary lymphoid structures associate with poor response
- Describe new, Raman chemometric urinalysis based method for bladder cancer screening
- Assess outcomes of radical cystectomy in those with variant histology
- Review bladder cancer epidemiology in Aboriginal and Torres strait Islanders
- Describe changes in body composition in patients receiving neoadjuvant chemotherapy for urothelial carcinoma
- Understand physician perceptions and practice patterns regarding thromboprophylaxis use during chemotherapy for bladder cancer
- Describe new risk factors for bladder cancer
- Appreciate how TURBT may be used as a tool to predict bladder cancer recurrence
Presentations
Dr. / Dr Jonathan Fadel
Analysis of sex-based differences in response to Bacillus Calmette Guérin for non-muscle invasive bladder cancer
Dr. / Dr Georgi Guruli
Raman chemometric urinalysis as a novel, low-cost and minimally invasive method for bladder cancer screening
Mrs. / Mme Raphaëlla Rosebush-Mercier
Pre-operative absolute basophils count predicts recurrence and progression of non-muscle invasive bladder cancer following Bacillus Calmette-Guérin (BCG) treatment
Ms. / Mme Mariève Lavallée
The anti-tumor effect of prebiotics in bladder cancer
Dr. / Dr Charles Hesswani
External validation of the molecular subtype classifier by immunohistochemistry for muscle invasive bladder cancer patients within the trimodal therapy cohort
Mr. / M. Kenneth Huang
The impact of routine bladder biopsies after Bacillus Calmette-Guerin treatment in patients with pure carcinoma in situ of the bladder
Dr. / Dr Sandra Kim
Impact of post-operative opioid use on length of hospital stay following radical cystectomy
Dr. / Dr Stephane Bolduc
Chronic exposure to bisphenol A could promote bladder cancer progression
Dr. / Dr Andrew Amenyogbe
A survey of physician perception and practices regarding pharmacologic thromboprophylaxis use during chemotherapy for bladder cancer
Dr. / Dr Ahmed Kotb
Radical cystectomy for bladder urothelial carcinoma with variant histology
Ms. / Mme Mariève Lavallée
Assessment of transurethral resection of a bladder tumor (TURBT) as a tool of detection for bladder cancer recurrence
Dr. / Dr Landan MacDonald
An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial carcinoma
Dr. / Dr Danielle Jenkins
Tumor adjacent tertiary lymphoid structures associate with poor response to BCG immunotherapy in non-muscle invasive bladder cancer
